|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...29303132333435363738394041» |
- memantine / Generic mfg.
Trial termination: Memantine-MS: Memantine Therapy for Multiple Sclerosis (clinicaltrials.gov) - Jun 6, 2012
P2, N=20, Terminated, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Suspended --> Terminated; Unexpected side-effects: reversible and mild to moderate neurological impairment
- | Plegridy (PEG-interferon ?-1a) / Biogen
New P1 trial: Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers (clinicaltrials.gov) - May 31, 2012
P1, N=30, Completed, Sponsor: Biogen Idec
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: ASPECT: Avonex PEN Satisfaction and Patients Experience Clinical Trial (clinicaltrials.gov) - May 30, 2012
P=N/A, N=89, Completed, Sponsor: Biogen Idec
Suspended --> Terminated; Unexpected side-effects: reversible and mild to moderate neurological impairment Active, not recruiting --> Completed
- | opicinumab (BIIB033) / Biogen
Trial completion, IO biomarker: Safety Study of BIIB033 in Subjects With Multiple Sclerosis (clinicaltrials.gov) - May 30, 2012
P1, N=47, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Sativex (nabiximols) / Jazz
New P3 trial: A Study of the Long-term Safety of Sativex Use (clinicaltrials.gov) - May 23, 2012
P3, N=507, Completed, Sponsor: GW Pharmaceuticals Ltd.
- ||| dexpramipexole (KNS-760704) / Knopp Biosciences, Biogen
Trial completion: Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate) (clinicaltrials.gov) - May 23, 2012
P1, N=68, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Recruiting --> Completed
- ||| ceralifimod (ONO 4641) / Ono Pharma
Enrollment closed: DreaMS: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - May 22, 2012
P2, N=343, Active, not recruiting, Sponsor: EMD Serono
Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- Trial completion: The Effects of Attention Retraining in MS (clinicaltrials.gov) - May 17, 2012
P=N/A, N=97, Completed, Sponsor: Finnish MS Society
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P3 trial: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - May 15, 2012
P3, N=185, Active, not recruiting, Sponsor: Allergan
- |||||||||| Sativex (nabiximols) / Jazz
New P3 trial: A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis (clinicaltrials.gov) - May 13, 2012
P3, N=337, Completed, Sponsor: GW Pharmaceuticals Ltd.
- ||||| dalfampridine / Generic mfg.
New P2 trial: Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (clinicaltrials.gov) - May 10, 2012
P2, N=132, Active, not recruiting, Sponsor: Biogen Idec
- |||| glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Trial completion: EXPLORE: BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis (clinicaltrials.gov) - May 9, 2012
P2, N=100, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ozanezumab (GSK 1223249) / GSK
Trial termination: NOGO-A in Multiple Sclerosis FTIH (clinicaltrials.gov) - May 9, 2012
P1, N=3, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Completed --> Terminated
- | dexpramipexole (KNS-760704) / Knopp Biosciences, Biogen
Trial completion: Dexpramipexole and Cimetidine Drug Drug Interaction (DDI) (clinicaltrials.gov) - May 9, 2012
P1, N=14, Completed, Sponsor: Biogen Idec
Completed --> Terminated Recruiting --> Completed
- Trial completion: Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 8, 2012
P1/2, N=50, Completed, Sponsor: Oregon Health and Science University
Recruiting --> Completed Recruiting --> Completed
- glatiramer acetate / Generic mfg.
Trial completion: Treatment of Multiple Sclerosis With Copaxone and Albuterol (clinicaltrials.gov) - May 6, 2012
P=N/A, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- Avonex (recombinant IFN-β-1a) / Biogen
Clinical: Evaluation of Brain Atrophy in CIS Patients on Avonex (clinicaltrials.gov) - May 3, 2012
P=N/A, N=180, Active, not recruiting, Sponsor: University at Buffalo
- ||| Biomarker: A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery (clinicaltrials.gov) - May 3, 2012
P=N/A, N=600, Recruiting, Sponsor: Sanguine Biosciences
- | Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness (clinicaltrials.gov) - May 2, 2012
P4, N=37, Completed, Sponsor: Cornerstone Health Care, PA
- autologous mesenchymal stem cells / Mayo Clinic, National Institute of Neurological Disorders and Stroke
Trial completion: Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - May 1, 2012
P1, N=1, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: Psychometric Validation of Cognitive Endpoints (clinicaltrials.gov) - Apr 30, 2012
P=N/A, N=60, Completed, Sponsor: Kessler Foundation
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion: BREAK: Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis (clinicaltrials.gov) - Apr 26, 2012
P=N/A, N=852, Completed, Sponsor: Bayer
Recruiting --> Completed Active, not recruiting --> Completed
- |||| Cosentyx (secukinumab) / Novartis
Trial completion: POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler (clinicaltrials.gov) - Apr 26, 2012
P2, N=73, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- || Avonex (recombinant IFN-β-1a) / Biogen
Enrollment change, HEOR, Adherence: Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=280, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Completed N=2000 --> 280
- | Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe
New P1 trial: Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 24, 2012
P1, N=28, Recruiting, Sponsor: MedImmune LLC
- | Cosentyx (secukinumab) / Novartis
Trial initiation date: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Apr 22, 2012
P2, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
N=2000 --> 280 Initiation date: Oct 2011 --> Feb 2012
- ||| Betaseron (IFN-β-1b) / Bayer
Enrollment open: Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (clinicaltrials.gov) - Apr 22, 2012
P=N/A, N=1300, Recruiting, Sponsor: Bayer
Initiation date: Oct 2011 --> Feb 2012 Not yet recruiting --> Recruiting
- | Cosentyx (secukinumab) / Novartis
Enrollment open: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Apr 22, 2012
P2, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || New P3 trial: RespiStimALS: Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation (clinicaltrials.gov) - Apr 19, 2012
P3, N=74, Recruiting, Sponsor: Assistance Publique - H
- || glatiramer acetate / Generic mfg.
New P3 trial: An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Apr 15, 2012
P3, N=178, Terminated, Sponsor: Teva Pharmaceutical Industries
- | New P4 trial, HEOR: A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 (clinicaltrials.gov) - Apr 12, 2012
P4, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
- Betaseron (IFN-β-1b) / Bayer
Trial withdrawal, HEOR: QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea (clinicaltrials.gov) - Apr 11, 2012
P=N/A, N=0, Withdrawn, Sponsor: Bayer
Not yet recruiting --> Recruiting Terminated --> Withdrawn
- ||| Avonex (recombinant IFN-?-1a) / Biogen
Trial completion: Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers (clinicaltrials.gov) - Apr 11, 2012
P1, N=110, Completed, Sponsor: Biogen Idec
Terminated --> Withdrawn Recruiting --> Completed
- | Qalsody (tofersen) / Biogen
Trial completion: SOD-1: Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations (clinicaltrials.gov) - Apr 11, 2012
P1, N=33, Completed, Sponsor: Isis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- Tysabri (natalizumab) / Biogen, Royalty
Enrollment change, MRI: Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri (clinicaltrials.gov) - Apr 10, 2012
P4, N=8, Terminated, Sponsor: University Hospital, Strasbourg, France
Active, not recruiting --> Completed N=20 --> 8
- Trial termination: Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis (clinicaltrials.gov) - Apr 8, 2012
P2, N=21, Terminated, Sponsor: Northwestern University
N=20 --> 8 Active, not recruiting --> Terminated
- ||||| everolimus / Generic mfg.
Trial initiation date: Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) (clinicaltrials.gov) - Apr 3, 2012
P3, N=118, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated Initiation date: Apr 2009 --> Aug 2009
- || Enrollment change, HEOR: An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers (clinicaltrials.gov) - Apr 2, 2012
P=N/A, N=141, Completed, Sponsor: Merck KGaA
Initiation date: Apr 2009 --> Aug 2009 N=450 --> 141
- ||| Trial completion, HEOR: An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers (clinicaltrials.gov) - Apr 2, 2012
P=N/A, N=141, Completed, Sponsor: Merck KGaA
N=450 --> 141 Active, not recruiting --> Completed
- | Rebif (human IFN-?-1a) / EMD Serono
Trial completion, MRI, Metastases: Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial (clinicaltrials.gov) - Apr 2, 2012
P4, N=38, Completed, Sponsor: EMD Serono
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
New P2 trial, Monotherapy: GATEWAY II: Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate (clinicaltrials.gov) - Apr 1, 2012
P2, N=90, Recruiting, Sponsor: University of Colorado, Denver
- rasagiline / Generic mfg.
Trial initiation date: Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 28, 2012
P2, N=30, Active, not recruiting, Sponsor: Yunxia Wang, MD
Active, not recruiting --> Completed Initiation date: Sep 2010 --> Dec 2011
- rasagiline / Generic mfg.
Enrollment change: Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 28, 2012
P2, N=30, Active, not recruiting, Sponsor: Yunxia Wang, MD
Initiation date: Sep 2010 --> Dec 2011 N=60 --> 30
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Enrollment open: Canadian Avonex PEN Productivity Study (clinicaltrials.gov) - Mar 28, 2012
P=N/A, N=500, Recruiting, Sponsor: Biogen Idec
N=60 --> 30 Not yet recruiting --> Recruiting
- rasagiline / Generic mfg.
Enrollment closed: Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 28, 2012
P2, N=30, Active, not recruiting, Sponsor: Yunxia Wang, MD
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg.
Enrollment change: High Dose Cyclophosphamide for Treatment of Scleroderma (clinicaltrials.gov) - Mar 28, 2012
P3, N=8, Completed, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting N=30 --> 8
- cyclophosphamide / Generic mfg.
Trial completion: High Dose Cyclophosphamide for Treatment of Scleroderma (clinicaltrials.gov) - Mar 28, 2012
P3, N=8, Completed, Sponsor: Johns Hopkins University
N=30 --> 8 Active, not recruiting --> Completed
- ||||| olesoxime (TRO19622) / Roche
Enrollment change: Safety Extension Study of TRO19622 in ALS (clinicaltrials.gov) - Mar 26, 2012
P2/3, N=271, Completed, Sponsor: Trophos
Active, not recruiting --> Completed N=350 --> 271
- Enrollment open: Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis (clinicaltrials.gov) - Mar 26, 2012
P=N/A, N=1920, Recruiting, Sponsor: University of California, San Francisco
N=350 --> 271 Not yet recruiting --> Recruiting
- ||||||| olesoxime (TRO19622) / Roche
Trial completion: Safety Extension Study of TRO19622 in ALS (clinicaltrials.gov) - Mar 26, 2012
P2/3, N=271, Completed, Sponsor: Trophos
Not yet recruiting --> Recruiting Recruiting --> Completed